Simultaneously, for other PARPi, on 30 June 2023, the FDA expanded approval for talazoparib to include the care of prostate cancer with mutations in multiple HRR pathway genes, such as BRCA1, BRCA2, PALB2, ATM, ATR, CHEK2, FANCA, RAD51C, NBN, MLH1, MRE11A, and CDK12 (Akbıyık and Ürün, 2023). This evidence concerns the gene PALB2 and Familial prostate cancer.